Kader Chouahnia

1.2k total citations
45 papers, 750 citations indexed

About

Kader Chouahnia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kader Chouahnia has authored 45 papers receiving a total of 750 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Kader Chouahnia's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (15 papers) and Colorectal Cancer Treatments and Studies (9 papers). Kader Chouahnia is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Research Studies (15 papers) and Colorectal Cancer Treatments and Studies (9 papers). Kader Chouahnia collaborates with scholars based in France, United States and United Kingdom. Kader Chouahnia's co-authors include Michaël Soussan, Boris Duchemann, Laurent Zelek, Jean‐François Morère, G. Des Guetz, Irène Buvat, Emmanuel Martinod, Fanny Orlhac, Lucas Goldfarb and Bernard Uzzan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Radiology.

In The Last Decade

Kader Chouahnia

43 papers receiving 738 citations

Peers

Countries citing papers authored by Kader Chouahnia

Since Specialization

Citations

This map shows the geographic impact of Kader Chouahnia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kader Chouahnia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kader Chouahnia more than expected).

Fields of papers citing papers by Kader Chouahnia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kader Chouahnia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kader Chouahnia. The network helps show where Kader Chouahnia may publish in the future.

Co-authorship network of co-authors of Kader Chouahnia

This figure shows the co-authorship network connecting the top 25 collaborators of Kader Chouahnia. A scholar is included among the top collaborators of Kader Chouahnia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kader Chouahnia. Kader Chouahnia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy 2023 ·Cancers ·(unknown), Romain‐David Seban, Kader Chouahnia, Jean‐Baptiste Assié, Laurence Champion, Nicolas Girard, G. Bonardel, (unknown), Michaël Soussan, C. Chouaïd, Boris Duchemann	2
2	Adoptive cell therapies in thoracic malignancies 2022 ·Cancer Immunology Immunotherapy ·(unknown), Marie Naigeon, Kader Chouahnia, Laurent Zelek, Nathalie Chaput, Boris Duchemann	8
3	Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report 2022 ·Frontiers in Oncology ·(unknown), (unknown), Antoine Martin, Kader Chouahnia, (unknown), (unknown), Boris Duchemann	3
4	First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation 2020 ·Journal of Cancer Research and Clinical Oncology ·Thierry Landré, Gaëtan Des Guetz, Kader Chouahnia, Boris Duchemann, Jean‐Baptiste Assié, C. Chouaïd	17
5	Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis 2020 ·Drugs & Aging ·Thierry Landré, G. Des Guetz, Kader Chouahnia, (unknown), Stéphane Culine	25
6	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers 2019 ·Journal of Cancer Research and Clinical Oncology ·Thierry Landré, Gaëtan Des Guetz, Kader Chouahnia, Chérifa Taleb, A. Vergnenègre, C. Chouaïd	9
7	Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST 2019 ·EJNMMI Research ·Lucas Goldfarb, Boris Duchemann, Kader Chouahnia, Laurent Zelek, Michaël Soussan	115
8	Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis 2019 ·Clinical Genitourinary Cancer ·Thierry Landré, G. Des Guetz, Kader Chouahnia, (unknown), Chérifa Taleb, Stéphane Culine	7
9	Le nivolumab peut-il être utilisé dans les fibroses pulmonaires idiopathiques ? 2019 ·Revue des Maladies Respiratoires ·Boris Duchemann, Morgane Didier, (unknown), Pierre‐Yves Brillet, Marianne Kambouchner, Y. Uzunhan, Olivia Freynet, Kader Chouahnia, Laurent Zelek, Hilario Nunès	10
10	18F-FDG PET-Derived Textural Indices Reflect Tissue-Specific Uptake Pattern in Non-Small Cell Lung Cancer 2015 ·PLoS ONE ·Fanny Orlhac, Michaël Soussan, Kader Chouahnia, Emmanuel Martinod, Irène Buvat	115
11	Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis 2015 ·Targeted Oncology ·G. Des Guetz, (unknown), Bernard Uzzan, Kader Chouahnia, Patrick Nicolas, Jean‐François Morère	15
12	Fluorine 18 Fluorodeoxyglucose PET/CT Volume-based Indices in Locally Advanced Non–Small Cell Lung Cancer: Prediction of Residual Viable Tumor after Induction Chemotherapy 2014 ·Radiology ·Michaël Soussan, Joanna Cyrta, (unknown), Kader Chouahnia, Fanny Orlhac, Emmanuel Martinod, Véronique Eder, Jean‐François Morère, Irène Buvat	18
13	Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy 2013 ·European Journal of Nuclear Medicine and Molecular Imaging ·Michaël Soussan, Kader Chouahnia, Jacques-Antoine Maisonobe, Marouane Boubaya, Véronique Eder, Jean‐François Morère, Irène Buvat	31
14	Airway transplantation: a challenge for regenerative medicine 2013 ·European journal of medical research ·(unknown), Emmanuel Martinod, Agathe Seguin, Dana M. Radu, Guillaume Boddaert, Kader Chouahnia, Anne Fialaire‐Legendre, Hervé Dutau, Nicolas Vénissac, Charles‐Hugo Marquette, Christophe Baillard, Dominique Valeyre, Alain Carpentier	24
15	Cardiovascular toxicity of anti-angiogenic drugs 2011 ·Targeted Oncology ·G. Des Guetz, Bernard Uzzan, Kader Chouahnia, Jean‐François Morère	45
16	Human Transplantation of a Biologic Airway Substitute in Conservative Lung Cancer Surgery 2011 ·The Annals of Thoracic Surgery ·Emmanuel Martinod, Dana M. Radu, Kader Chouahnia, Agathe Seguin, Anne Fialaire‐Legendre, Pierre‐Yves Brillet, (unknown), Georges Sebbane, Sadek Béloucif, Dominique Valeyre, Christophe Baillard, Alain Carpentier	23
17	Les métastases cérébrales des cancers bronchiques non à petites cellules : vers une prise en charge homogène 2011 ·Revue Neurologique ·Olivier Bailon, (unknown), Kader Chouahnia, S. Billot, David M. Ferrari, Alain Carpentier	6
18	Tumor Lysis Associated with Sudden Onset of Syndrome of Inappropriate Antidiuretic Hormone Secretion 2007 ·Clinical Lung Cancer ·Pierre Saintigny, Kader Chouahnia, R. Cohen, (unknown), (unknown), Jean‐François Morère, (unknown)	10
19	Géfitinib et méningite carcinomateuse d’un carcinome bronchique non à petites cellules (CBNPC) 2006 ·Revue des Maladies Respiratoires ·Kader Chouahnia, J.-M. Bréchot, (unknown), Pierre Saintigny, Jean‐François Morère, J.L. Breau	2
20	Métastase splénique d’un carcinome du sinus piriforme 2004 ·Journal de Chirurgie ·Kader Chouahnia, G. Des Guetz, T. Bouillet, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact